|
DrugPatentWatch concentrates deep knowledge on more than 6,400 small-molecule drugs and 2,300 generic ingredients from 1,700 branded and generic pharmaceutical companies and 700 suppliers, and more than 4,300 active and expired US patents and 74,000 international patents spanning 93 countries and regional patent offices. |
Generic Name: sibutramine hydrochloride
Clinical Trials for: sibutramine hydrochlorideWeight Loss in Response to Sibutramine (MERIDIA) is Influenced by the Inherited Genes Status: Completed Condition: Obesity Sibutramine-metformin Combination Versus Sibutramine and Metformin Monotherapy in Obese Patients Status: Active, not recruiting Condition: Obesity Effects of Clopidogrel and Clarithromycin on the Oral Disposition of Sibutramine in Healthy Subjects Status: Completed Condition: Healthy A Long Term Study of Sibutramine and the Role of Obesity Management in Relation to Cardiovascular Disease in Overweight and Obese Patients Status: Completed Condition: Obesity Blood Pressure and Weight Trajectory on a Dual Antihypertensive Combination Plus Sibutramine Versus Placebo in Obese Hypertensives Status: Completed Condition: Obesity; Hypertension Study to Examine the Longer-Term Efficacy and Safety of Sibutramine Hydrochloride in Obese Subjects Status: Terminated Condition: Obesity; Weight Loss Studying the Effects of Sibutramine on Eating Behavior Status: Terminated Condition: Obesity Assess the Additional Weight Loss Effect of Orlistat Used in Combination With Sibutramine Status: Completed Condition: Obesity A Study to Examine the Efficacy and Safety of Meridia® (Sibutramine Hydrochloride) in Binge-Eating Disorder Status: Completed Condition: Binge Eating Disorder; Obesity Efficacy and Safety Study of Sibutramine in Overweight Non-Diabetic Malaysian Population Status: Completed Condition: Obesity Courtesy of ClinicalTrials.org See more clinical trials for this drug | |
Glossary
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Type | RLD | Patent No. | Product | Substance | Delist_Flag | Patent Expiration | Patented / Exclusive Use | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Abbott | MERIDIA | sibutramine hydrochloride | CAPSULE; ORAL | 020632 | Nov 22, 1997 | DISCN | No | 5,436,272*PED | Y | <disabled> | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| The preview shows a limited data set. Complete access is available with a Subscription | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
« Back to Dashboard
DrugPatentWatch Archives
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Connect with Social Media:
Copyright © 2002-2013 thinkBiotech LLC. ISSN: 2162-2639
`abc